Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Colorectal Neoplasms

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 46 articles: HTML format

Single Articles

June 2025
1. SHAMSEDDINE A, Turfa R, Chehade L, Zeidan YH, et al
   Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study.
   Eur J Cancer. 2025;222:115428.
   PubMed     Abstract available
   
   
   May 2025
2. HAFLIGER E, Nili-Asgari R, Netter J, Taieb J, et al
   Case report of two fatal cerebral hemorrhages in patients with metastatic colorectal cancer treated with Fruquintinib.
   Eur J Cancer. 2025 May 19:115517. doi: 10.1016/j.ejca.2025.115517.
   PubMed    
   
   
   April 2025
3. MORETTO R, Rossini D, Polito MG, Antoniotti C, et al
   The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.
   Eur J Cancer. 2025;222:115470.
   PubMed     Abstract available
   
   
   
4. PIZZAMIGLIO M, Soulabaille A, Lahlou W, Pilla L, et al
   Advances and challenges in targeted therapies for HER2-amplified colorectal cancer.
   Eur J Cancer. 2025;222:115471.
   PubMed     Abstract available
   
   
   
5. NORONHA MM, Costa Almeida LF, Cappellaro AP, Silva LFLD, et al
   Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis of randomized controlled trials.
   Eur J Cancer. 2025;222:115476.
   PubMed     Abstract available
   
   
   
6. JORGENSEN SF, Njor SH, Nevala A, Palsson B, et al
   Nordic colorectal cancer screening programmes: A comparison of organization, operation, and quality indicators.
   Eur J Cancer. 2025;222:115444.
   PubMed     Abstract available
   
   
   
7. WEISS L, Stintzing S, Stahler A, Benedikt Westphalen C, et al
   Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
   Eur J Cancer. 2025;221:115399.
   PubMed     Abstract available
   
   
   March 2025
8. HOLCH JW, Ohnmacht AJ, Stintzing S, Heinrich K, et al
   FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
   Eur J Cancer. 2025;220:115388.
   PubMed     Abstract available
   
   
   
9. MORETTO R, Boccaccio C, Landi M, Masi G, et al
   Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal cancer. A narrative review and evidence-based algorit
   Eur J Cancer. 2025;218:115261.
   PubMed     Abstract available
   
   
   
10. CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al
    Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience.
    Eur J Cancer. 2025;220:115344.
    PubMed     Abstract available
    
    
    February 2025
11. POUMEAUD F, Valentin T, Fares N, Segier B, et al
    Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.
    Eur J Cancer. 2025;216:115196.
    PubMed     Abstract available
    
    
    
12. QIU X, Zhou J, Qiu H, Shen Z, et al
    A new treatment strategy for mid-low rectal cancer patients exhibiting a clinical complete or near-complete response to neoadjuvant chemoradiotherapy: Transanal endoscopic microsurgery --A multicenter prospective case-control clinical trial by MONT-R.
    Eur J Cancer. 2025;216:115156.
    PubMed     Abstract available
    
    
    January 2025
13. SOBRERO A, Dasari A, Aquino J, Lonardi S, et al
    Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.
    Eur J Cancer. 2025;218:115268.
    PubMed     Abstract available
    
    
    
14. WANG DS, Pat Fong W, Wen L, Cai YY, et al
    Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial.
    Eur J Cancer. 2025;214:115154.
    PubMed     Abstract available
    
    
    December 2024
15. CARBONE F, Spinelli A, Ciardiello D, Realis Luc M, et al
    Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis.
    Eur J Cancer. 2024;215:115172.
    PubMed     Abstract available
    
    
    
16. TOUGERON D, Bibeau F, Chibaudel B, Kim S, et al
    Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort.
    Eur J Cancer. 2024;213:115082.
    PubMed     Abstract available
    
    
    November 2024
17. HIRANO H, Kataoka K, Yamaguchi T, Wagner AD, et al
    Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A).
    Eur J Cancer. 2024;214:115139.
    PubMed     Abstract available
    
    
    
18. DUNN C, Shapiro J, Lee M, Wong R, et al
    Measuring quality in the care of metastatic colorectal cancer utilising available registry data: A modified Delphi study.
    Eur J Cancer. 2024;214:115142.
    PubMed     Abstract available
    
    
    
19. XIAO A, Li X, Wang C, Ye J, et al
    Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial.
    Eur J Cancer. 2024;213:115111.
    PubMed     Abstract available
    
    
    
20. SUN L, Xu Y, Chen N, Zhang C, et al
    Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial.
    Eur J Cancer. 2024;213:115109.
    PubMed     Abstract available
    
    
    
21. FRYDENDAHL A, Nors J, Rasmussen MH, Henriksen TV, et al
    Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients.
    Eur J Cancer. 2024;211:114314.
    PubMed     Abstract available
    
    
    October 2024
22. STINTZING S, Yoshino T
    Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024;210:114298.
    PubMed    
    
    
    
23. FOKAS E, Williams H, Diefenhardt M, Lin S, et al
    Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials.
    Eur J Cancer. 2024;210:114291.
    PubMed     Abstract available
    
    
    September 2024
24. SMABERS LP, Huismans MA, van Nieuwenhuijzen N, Minnema MC, et al
    Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysis.
    Eur J Cancer. 2024;212:115059.
    PubMed     Abstract available
    
    
    
25. MARGALIT O, Stemmer A, Chapin WJ, Shacham-Shmueli E, et al
    Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients.
    Eur J Cancer. 2024;212:114336.
    PubMed     Abstract available
    
    
    
26. BOTTA L, Capocaccia R, Bernasconi A, Rossi S, et al
    Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers.
    Eur J Cancer. 2024;208:114187.
    PubMed     Abstract available
    
    
    August 2024
27. AMBROSINI M, Tougeron D, Modest D, Guimbaud R, et al
    BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.
    Eur J Cancer. 2024;210:114290.
    PubMed     Abstract available
    
    
    
28. XIE Z, Lin H, Huang Y, Wang X, et al
    BAP1-mediated MAFF deubiquitylation regulates tumor growth and is associated with adverse outcomes in colorectal cancer.
    Eur J Cancer. 2024;210:114278.
    PubMed     Abstract available
    
    
    
29. ZHANG P, Han Y, Cai Z, Cao D, et al
    Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024 Aug 6:114266. doi: 10.1016/j.ejca.2024.114266.
    PubMed    
    
    
    
30. MICHIEL ZEEUW J, Wesdorp NJ, Ali M, Bakker AJJ, et al
    Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation.
    Eur J Cancer. 2024;207:114185.
    PubMed     Abstract available
    
    
    July 2024
31. FRANKEN IA, van der Baan FH, Vink GR, May AM, et al
    Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months.
    Eur J Cancer. 2024;208:114207.
    PubMed     Abstract available
    
    
    June 2024
32. MERCIER L, Delaye M, Fuerea A, Ducreux M, et al
    Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer.
    Eur J Cancer. 2024;208:114193.
    PubMed    
    
    
    
33. ANDERSEN L, Kisistok J, Henriksen TV, Bramsen JB, et al
    Exploring the biology of ctDNA release in colorectal cancer.
    Eur J Cancer. 2024;207:114186.
    PubMed     Abstract available
    
    
    
34. SWARTJES H, Sijtsma FPC, Elferink MAG, van Erning FN, et al
    Corrigendum to "Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021'' Volume 205, July 2024, 114104.
    Eur J Cancer. 2024 Jun 11:114155. doi: 10.1016/j.ejca.2024.114155.
    PubMed    
    
    
    
35. COHEN R, Raeisi M, Chibaudel B, Shi Q, et al
    Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
    Eur J Cancer. 2024;207:114160.
    PubMed     Abstract available
    
    
    
36. ZWART WH, Temmink SJD, Hospers GAP, Marijnen CAM, et al
    Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial.
    Eur J Cancer. 2024;204:114044.
    PubMed     Abstract available
    
    
    May 2024
37. CHEN C, Feng YS, Wang Z, Gupta M, et al
    Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer.
    Eur J Cancer. 2024;207:114147.
    PubMed     Abstract available
    
    
    
38. TAIEB J, Basile D, Seligmann J, Argiles G, et al
    Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts.
    Eur J Cancer. 2024;206:114118.
    PubMed     Abstract available
    
    
    
39. SWARTJES H, Sijtsma FPC, Elferink MAG, van Erning FN, et al
    Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021.
    Eur J Cancer. 2024;205:114104.
    PubMed     Abstract available
    
    
    
40. MOREAU M, Alouani E, Flecchia C, Falcoz A, et al
    A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
    Eur J Cancer. 2024;202:114033.
    PubMed     Abstract available
    
    
    
41. VAN GEFFEN EGM, Langhout JMA, Hazen SJA, Sluckin TC, et al
    Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohorts.
    Eur J Cancer. 2024;202:114021.
    PubMed     Abstract available
    
    
    March 2024
42. TAKASHIMA A, Garcia-Alfonso P, Manneh R, Besen AA, et al
    Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
    Eur J Cancer. 2024;205:114036.
    PubMed     Abstract available
    
    
    
43. BARBE R, Belkouchi Y, Menu Y, Cohen R, et al
    Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
    Eur J Cancer. 2024;202:114020.
    PubMed     Abstract available
    
    
    
44. SPIEKMAN IAC, Zeverijn LJ, Geurts BS, Verkerk K, et al
    Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
    Eur J Cancer. 2024;202:113988.
    PubMed     Abstract available
    
    
    
45. LI L
    Comment on: Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer.
    Eur J Cancer. 2024;202:113982.
    PubMed    
    
    
    
46. YOSHINO T, Hooda N, Younan D, Muro K, et al
    A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024;202:113975.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.